1
|
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. Br J Cancer 2022; 127:92-101. [PMID: 35568736 PMCID: PMC9276671 DOI: 10.1038/s41416-022-01780-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 02/15/2022] [Accepted: 03/02/2022] [Indexed: 01/04/2023] Open
Abstract
Background We aimed to assess the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide. Methods We used an open-label, multicentre, dose-escalation Phase I trial design in patients with solid tumours. ALM201 was administered subcutaneously once daily for 5 days every week in unselected patients with solid tumours. Results Twenty (8 male, 12 female) patients with various solid tumours were treated (18 evaluable for toxicity) over eight planned dose levels (10–300 mg). ALM201 was well-tolerated at all dose levels without CTCAE grade 4 toxicities. Adverse events were predominantly grades 1–2, most commonly, localised injection-site reactions (44.4%), vomiting (11%), fatigue (16.7%), arthralgia (5.6%) and headache (11%). Thrombosis occurred in two patients at the 100 mg and 10 mg dose levels. The MTD was not reached, and a recommended Phase II dose (RP2D) based on feasibility was declared. Plasma exposure increased with dose (less than dose-proportional at the two highest dose levels). No peptide accumulation was evident. The median treatment duration was 11.1 (range 3–18) weeks. Four of 18 evaluable patients (22%) had stable disease. Conclusions Doses up to 300 mg of ALM201 subcutaneously are feasible and well-tolerated. Further investigation of this agent in selected tumour types/settings would benefit from patient-selection biomarkers.
Collapse
|
2
|
Lam SY, Lee CS, Sharma S, Cheng K. Bevacizumab-induced dysphonia: A case report with brief review of literature. J Oncol Pharm Pract 2019; 26:1032-1036. [PMID: 31771464 DOI: 10.1177/1078155219889388] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Anti-angiogenic treatment in adjunct with chemotherapy is widely used for the treatment of various cancers. These agents inhibit vascular endothelial growth factor (VEGF) signaling thereby inhibiting tumor proliferation and invasion. Dysphonia, or voice changes, has been documented, but is an underreported side effect of anti-angiogenic agents. We report a case of intermittent dysphonia in a patient with metastatic, platinum-refractory ovarian cancer treated with bevacizumab. CASE REPORT A 48-year-old female with high grade mixed type ovarian adenocarcinoma and concurrent left sided breast cancer was transitioned to palliative therapy with gemcitabine-bevacizumab for her ovarian cancer. At a follow-up visit after three cycles of the new therapy, the patient complained of intermittent changes in her voice, describing periods of hoarseness or softness in her voice after the chemotherapy-sometimes to the point that her voice was inaudible. Management and outcome: A new pelvic thrombus was discovered upon assessment of the patient's disease. Bevacizumab was held and she was referred to ear, nose, and throat evaluation for dysphonia. Laryngoscopic examination showed normal vocal cord, with normal movements and no lesion or necrosis. During subsequent follow-up, the patient reported improvement in her voice with no additional dysphonia. DISCUSSION Vocal adverse effects of anti-VEGF agents have been documented in landmark trials and case reports; however, clinicians are often unaware of this rare side effect. Although VEGF-induced dysphonia may be rare and may not impede the patient's quality of life in some cases, it is critical to acknowledge and not underestimate this adverse effect.
Collapse
Affiliation(s)
- So Yi Lam
- St. John's University, New York, NY, USA
| | - Chung-Shien Lee
- Department of Clinical Health Professions, St. John's University College of Pharmacy and Health Sciences, New York, NY, USA
| | | | - Kit Cheng
- Monter Cancer Center of Northwell Health, New York, NY, USA
| |
Collapse
|
3
|
Melo ÉGA, Silveira PAL, Mello CA. Transient vocal fold lesion and hoarseness associated with the use of ramucirumab: Case report. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136:317-319. [PMID: 30876850 DOI: 10.1016/j.anorl.2018.08.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Revised: 08/17/2018] [Accepted: 08/27/2018] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Gastric cancer (GC) is among the leading neoplasms with highest morbidity and mortality in the world. Tumor angiogenesis represents one of important targets of antineoplastic treatment, as it has an important role in cell development and growth. CASE REPORT Ramucirumab, an IgG1 monoclonal antibody (MoAb), inhibits the angiogenesis pathway by blocking the VEGFR-2 activation. The most common adverse events associated with angiogenic inhibitors are cardiovascular and healing disorders, such as systemic arterial hypertension (HTN), thromboembolism, bleeding, wound healing delay and fistulas. We report a case of vocal fold lesion associated with ramucirumab in a patient with metastatic gastric cancer. The patient presented with transient hoarseness that was related to the exposure to ramucirumab. DISCUSSION Laryngeal toxicity due to anti-angiogenic agents is rare. Despite the fact that this adverse event is not a life-threatening complication, it can significantly impair quality of life and should be promptly recognized.
Collapse
Affiliation(s)
- É G A Melo
- Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, SP, Brazil.
| | - P A L Silveira
- Department of Otorrinolaryngology, AC Camargo Cancer Center, São Paulo, SP, Brazil
| | - C A Mello
- Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, SP, Brazil
| |
Collapse
|
4
|
Meng Q, Li Z. Molecular imaging probes for diagnosis and therapy evaluation of breast cancer. Int J Biomed Imaging 2013; 2013:230487. [PMID: 23533377 PMCID: PMC3600346 DOI: 10.1155/2013/230487] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Revised: 12/27/2012] [Accepted: 01/09/2013] [Indexed: 12/16/2022] Open
Abstract
Breast cancer is a major cause of cancer death in women where early detection and accurate assessment of therapy response can improve clinical outcomes. Molecular imaging, which includes PET, SPECT, MRI, and optical modalities, provides noninvasive means of detecting biological processes and molecular events in vivo. Molecular imaging has the potential to enhance our understanding of breast cancer biology and effects of drug action during both preclinical and clinical phases of drug development. This has led to the identification of many molecular imaging probes for key processes in breast cancer. Hormone receptors, growth factor receptor, and angiogenic factors, such as ER, PR, HER2, and VEGFR, have been adopted as imaging targets to detect and stage the breast cancer and to monitor the treatment efficacy. Receptor imaging probes are usually composed of targeting moiety attached to a signaling component such as a radionuclide that can be detected using dedicated instruments. Current molecular imaging probes involved in breast cancer diagnosis and therapy evaluation are reviewed, and future of molecular imaging for the preclinical and clinical is explained.
Collapse
Affiliation(s)
- Qingqing Meng
- Department of Translational Imaging, The Methodist Hospital Research Institute, Weill Cornell Medical College, 6670 Bertner Avenue, Houston, TX 77030, USA
| | - Zheng Li
- Department of Translational Imaging, The Methodist Hospital Research Institute, Weill Cornell Medical College, 6670 Bertner Avenue, Houston, TX 77030, USA
| |
Collapse
|
5
|
Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. Clin Cancer Res 2012; 18:6364-72. [PMID: 23014528 DOI: 10.1158/1078-0432.ccr-12-1499] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE In this first-in-human study of AEE788, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), HER-2, and VEGFR-2, a comprehensive pharmacodynamic program was implemented in addition to the evaluation of safety, pharmacokinetics, and preliminary efficacy of AEE788 in cancer patients. EXPERIMENTAL DESIGN Patients with advanced, solid tumors received escalating doses of oral AEE788 once daily. Primary endpoints were to determine dose-limiting toxicities (DLTs) and maximum-tolerated dose (MTD). A nonlinear model (Emax model) was used to describe the relationship between AEE788 exposure and target-pathway modulation in skin and tumor tissues. RESULTS Overall, 111 patients were treated (25 to 550 mg/day). DLTs included rash and diarrhea; MTD was 450 mg/day. Effects on biomarkers correlated to serum AEE788 concentrations. The concentration at 50% inhibition (IC(50)) for EGFR in skin (0.033 μmol/L) and tumor (0.0125 μmol/L) were similar to IC(50) in vitro suggesting skin may be surrogate tissue for estimating tumor EGFR inhibition. No inhibition of p-MAPK and Ki67 was observed in skin vessels at ≤ MTD. Hence, AEE788 inhibited EGFR, but not VEGFR, at doses ≤ MTD. A total of 16 of 96 evaluable patients showed a >10% shrinkage of tumor size; one partial response was observed. CONCLUSION Our pharmacodynamic-based study showed effective inhibition of EGFR, but not of VEGFR at tolerable AEE788 doses. Emax modeling integrated with biomarker data effectively guided real-time decision making in the early development of AEE788. Despite clinical activity, target inhibition of only EGFR led to discontinuation of further AEE788 development.
Collapse
Affiliation(s)
- José Baselga
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Hartl DM, Bahleda R, Hollebecque A, Bosq J, Massard C, Soria JC. Bevacizumab-induced laryngeal necrosis. Ann Oncol 2012; 23:276-278. [PMID: 22056850 DOI: 10.1093/annonc/mdr515] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Affiliation(s)
- D M Hartl
- Department of Head and Neck Oncology, Institut Gustave Roussy, Villejuif.
| | - R Bahleda
- Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif
| | - A Hollebecque
- Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif
| | - J Bosq
- Department of Pathology, Institut Gustave Roussy, Villejuif, France
| | - C Massard
- Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif
| | - J C Soria
- Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif
| |
Collapse
|
7
|
Zhou HB, Yin YF, Hu Y, Li X, Zou LY, Li YJ, Gu Y, Ou BQ, Fu J, Du JH, Wu G. Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells. Jpn J Radiol 2011; 29:615-22. [PMID: 21956366 DOI: 10.1007/s11604-011-0603-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2010] [Accepted: 04/25/2011] [Indexed: 10/17/2022]
Abstract
PURPOSE The aim was to study the effect of vascular endothelial growth factor (VEGF) down-regulation by small interfering (si)RNA-mediated interference (RNAi) on the biological features of nasopharyngeal carcinoma cell line CNE-2. MATERIALS AND METHODS The combined plasmids pU-siVEGF and pU-siCONT were transfected into CNE-2 cells with lipofectamine. The transfected cells were placed in fresh medium containing G418. Expression of VEGF mRNA and protein were measured by reverse transcriptase-polymerase chain reaction and Western blot, respectively. The transwell chamber model was employed to test the ability of cell invasion in vitro. The distribution of cell cycle phases was determined by flow cytometry. Cell survival was assessed by clonogenic assays. RESULTS Both VEGF mRNA and protein expression were significantly decreased in the pU-siVEGF group compared with controls (P < 0.05). The cell cycle was arrested in the G(1) phase (P < 0.05). A higher apoptotic ratio and lower invasion ability were seen in the pU-siVEGF group. The D(0) (mean lethal dose) and SF(2) values were significantly lower than those in the control group (P < 0.05). CONCLUSION Delivery of siRNA targeting VEGF seems efficient in down-regulating VEGF expression and diminishing the growth, proliferation, and invasiveness of CNE-2 cells. It also enhanced the sensitivity of CNE-2 cells to radiation.
Collapse
Affiliation(s)
- Hai B Zhou
- Department of Radiation and Medical Oncology, Second Hospital of Yichang, 4 Tiyuchang Road, Yichang, Hubei 443000, China.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Duan WR, Patyna S, Kuhlmann MA, Li S, Blomme EAG. A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice. J INVEST SURG 2009; 19:245-54. [PMID: 16835139 DOI: 10.1080/08941930600778248] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Disturbances of angiogenesis have been suggested to result in the impaired healing of skin wounds. Using a murine incisional wound model, we evaluated the effects of SU6668, an inhibitor of the receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), on the healing of skin wounds. Mice were administered vehicle, SU6668 (100 or 400 mg/kg/day, b.i.d.), or dexamethasone (1 mg/kg/day, b.i.d.), and wound healing was monitored histologically and using a tensiometer. SU6668 at a fully efficacious dose of 100 mg/kg/day had no significant effect on the healing process, while at a supratherapeutic dose of 400 mg/kg/day, there were subtle transient histologic changes and slight decreases in tensile strength, suggesting a slight delay in the wound healing process. In conclusion, these data indicate that inhibition of the receptors for VEGF, PDGF, and FGF at levels necessary to inhibit tumor growth in mouse xenograft models does not affect the healing of incisional wounds in mice. Redundant pathways likely compensate for inhibition of VEGF, PDGF, and FGF signaling pathways in the skin healing process.
Collapse
|
9
|
Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2009; 28:23S-30S. [PMID: 18980549 DOI: 10.1592/phco.28.11-supp.23s] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Abstract Vascular endothelial growth factor (VEGF) is the most potent proangiogenic factor and has been identified as an important target of cancer therapy. Blocking endothelial cell VEGF activity inhibits tumor angiogenesis; normalizes tumor vasculature, facilitating improved chemotherapy delivery; and prevents the recruitment of progenitor cells from the bone marrow. Bevacizumab, the only United States Food and Drug Administration (FDA)-approved anti-VEGF agent, is a monoclonal antibody that inhibits the binding of VEGF to VEGF receptors. The addition of bevacizumab to standard first- and second-line chemotherapy regimens for the treatment of metastatic colorectal cancer improves overall and progression-free survival times and increases the time to disease progression. Studies are evaluating bevacizumab as adjuvant therapy. The optimal bevacizumab dosage is unknown, but 5 mg/kg every 2 weeks is currently recommended for initial therapy. A surrogate efficacy marker is needed to optimize bevacizumab use, both for dose and patient selection; the clinical applicability of several surrogate efficacy markers is being evaluated. Generally, bevacizumab is well tolerated; however, several serious adverse effects that may occur (e.g., hypertensive crisis) can usually be appropriately prevented or managed. Although current recommendations suggest the administration of the first bevacizumab dose over 90 minutes to prevent infusion-related hypersensitivity reactions, recent study results show that 5 and 10 mg/kg can safely be administered over 10 and 20 minutes, respectively. Whether the addition of bevacizumab to metastatic colorectal cancer treatment regimens is a cost-effective treatment option is unknown; health economic studies are needed. When used for FDA-approved indications or for off-label indications being evaluated in select clinical trials, Medicare reimburses for bevacizumab therapy.
Collapse
Affiliation(s)
- Judy L Chase
- Clinical Pharmacy Services, Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
| |
Collapse
|
10
|
Chekhonin VP, Baklaushev VP, Yusubalieva GM, Gurina OI. Targeted Transport of 125I-Labeled Antibody to GFAP and AMVB1 in an Experimental Rat Model of C6 Glioma. J Neuroimmune Pharmacol 2008; 4:28-34. [DOI: 10.1007/s11481-008-9123-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2008] [Accepted: 08/13/2008] [Indexed: 12/13/2022]
|
11
|
Chekhonin VP, Baklaushev VP, Yusubalieva GM, Pavlov KA, Ukhova OV, Gurina OI. Modeling and immunohistochemical analysis of C6 glioma in vivo. Bull Exp Biol Med 2008; 143:501-9. [PMID: 18214311 DOI: 10.1007/s10517-007-0167-y] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
A reproducible in vivo model of C6 glioma was developed in Wistar rats. Analysis of histological preparations showed similar morphology of rat C6 glioma and human glioblastoma. The formation of a glial border at the periphery of the glioma, consisting of GFAP-positive reactive astrocytes, was shown by the immunohistochemical method. The border appeared on day 8 after implantation, astrogliosis was observed until animal death (day 28). Reactive astrocytes with branched processes surrounded not only the primary glioma focus, but also all sites of tumor invasion in the nervous tissue. Expression of EBA (blood-brain barrier marker) was disturbed and synthesis of AMVB1 (endothelial antigen) increased in neoplastic endotheliocytes, which suggested pronounced functional restructuring of the blood-tumor barrier in comparison with the blood-brain barrier. The phenomenon of predominant expression of GFAP and AMVB in the tumor tissue can be used for the development of systems for targeted drug transport into the tumor by means of appropriate antibodies.
Collapse
Affiliation(s)
- V P Chekhonin
- Laboratory of Immunochemistry, V. P. Serbsky National Research Centre for Social and Forensic Psychiatry, Federal Agency for Health Care and Social Development, Moscow
| | | | | | | | | | | |
Collapse
|
12
|
Shimizu K, Sawazaki Y, Tanaka T, Asai T, Oku N. Chronopharmacologic Cancer Treatment with an Angiogenic Vessel-Targeted Liposomal Drug. Biol Pharm Bull 2008; 31:95-8. [DOI: 10.1248/bpb.31.95] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Kosuke Shimizu
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences
| | - Yasuharu Sawazaki
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences
| | - Toshiki Tanaka
- Department of Applied Chemistry, Faculty of Engineering, Nagoya Institute of Technology
| | - Tomohiro Asai
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences
| | - Naoto Oku
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences
| |
Collapse
|
13
|
Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z, Wang S, Nör JE. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2007; 66:8698-706. [PMID: 16951185 DOI: 10.1158/0008-5472.can-05-3691] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Bcl-2 is an antiapoptotic protein that is up-regulated in several tumor types, and its expression levels have strong correlation to development of resistance to therapy and poor prognosis. We have shown recently that Bcl-2 also functions as a proangiogenic signaling molecule that activates a nuclear factor-kappaB-mediated pathway resulting in up-regulation of the angiogenic chemokines CXCL1 and CXCL8 by neovascular endothelial cells. Here, we evaluate the antiangiogenic effect of the novel small-molecule inhibitor of Bcl-2 (TW37) developed using a structure-based design strategy. We observed that TW37 has an IC(50) of 1.8 mumol/L for endothelial cells but showed no cytotoxic effects for fibroblasts at concentrations up to 50 mumol/L. The mechanism of TW37-induced endothelial cell death was apoptosis, in a process mediated by mitochondrial depolarization and activation of caspase-9 and caspase-3. The effect of TW37 on endothelial cell apoptosis was not prevented by coexposure to the growth factor milieu secreted by tumor cells. Inhibition of the angiogenic potential of endothelial cells (i.e., migration and capillary sprouting assays) and expression of the angiogenic chemokines CXCL1 and CXCL8 were accomplished at subapoptotic TW37 concentrations (0.005-0.05 micromol/L). Notably, administration of TW37 i.v. resulted in a decrease in the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. In conclusion, we describe functionally separate proapoptotic and antiangiogenic mechanisms for a small-molecule inhibitor of Bcl-2 and show the potential for Bcl-2 inhibition as a target for antiangiogenic therapy.
Collapse
Affiliation(s)
- Benjamin D Zeitlin
- Angiogenesis Research Laboratory, Department of Restorative Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI 48109-1078, USA
| | | | | | | | | | | | | | | |
Collapse
|